Cagrilintide Dose and Frequency: Actual Trial Schedules and Results
Compare registered phase 2 escalation with combination-trial schedules, seven weight-change rows and target versus attained doses in REDEFINE 1.
FormBlends Editorial Research · Updated 2026-10-03
Retatrutide research context
Retatrutide is investigational, is not FDA-approved and cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell it. Percentages from separate trials do not establish superiority, and an average does not predict an individual outcome. The cited evidence does not establish sex-specific regimens or validate combinations with other drugs. No FDA approval date has been established.
Key Takeaways
- Cagrilintide is investigational and not FDA-approved; there is no approved patient dose
- Phase 2 trials tested 0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly; later REDEFINE 1 studied a 2.4 mg target with dose flexibility
- The drug is injected subcutaneously once weekly, similar to semaglutide and tirzepatide schedules
- Escalation differs by assigned target and by monotherapy versus combination study
- FormBlends does not prescribe or supply cagrilintide; trial dosing is research protocol, not patient guidance
Direct answer
The 2021 monotherapy trial tested cagrilintide target doses of 0.3, 0.6, 1.2, 2.4 and 4.5 mg by once-weekly subcutaneous injection. Its escalation differed from the combination studies. The registered 2.4 mg group started at 0.6 mg and reached 2.4 mg at week 4, not a universal 0.3 mg start followed by the nine-week schedule previously shown. Cagrilintide is investigational and not FDA-approved. There is no patient-approved dose; trial dosing should not be interpreted as a self-administration protocol.
Table of contents
- Important framing: what "dose" means for an investigational drug
- Dose ranges tested in published trials
- Why 2.4 mg became the focus dose
- The titration schedule used in trials
- Injection technique and frequency
- Why dose-response flattens at higher doses
- How CagriSema combines cagrilintide and semaglutide dosing
- The gray-market dosing problem
- The contrary view: dose may differ in commercial labeling
- Decision framework for patients considering trials
- FAQ
- Sources
Important framing: what "dose" means for an investigational drug
This article describes doses studied in clinical trials. None of these doses constitute medical guidance or a self-administration protocol. Several reasons matter:
First, cagrilintide is investigational. It is not FDA-approved. There is no labeling, no patient information leaflet, and no prescriber guidance. Any use outside an authorized clinical trial is unauthorized.
Second, trial doses are administered under medical supervision. Patients in trials are monitored for tolerability, blood pressure, vital signs, lab abnormalities, and adverse events. Self-administration outside of supervision lacks all of these safety nets.
Third, trial products are quality-tested. The cagrilintide used in clinical trials is manufactured under FDA-recognized standards. Products labeled as cagrilintide from gray-market sources do not have verified identity, purity, or sterility.
Fourth, trial dosing protocols include titration steps that minimize side effects. Skipping titration produces nausea and vomiting at rates that lead many patients to discontinue or to develop dehydration and electrolyte complications.
If you are interested in cagrilintide for weight management, the appropriate path is to discuss with your clinician and, if relevant, to ask about enrollment in active clinical trials (clinicaltrials.gov has the most current listing).
Dose ranges tested in published trials
The pivotal phase 2 monotherapy trial (Lau et al., The Lancet 2021) tested five active doses against placebo and a liraglutide comparator.
| Assigned group | Contributing participants | Mean change | Standard deviation |
|---|---|---|---|
| Cagrilintide 0.3 mg | 96 | -6.1% | 3.9 |
| Cagrilintide 0.6 mg | 97 | -6.9% | 5.4 |
| Cagrilintide 1.2 mg | 98 | -8.5% | 5.4 |
| Cagrilintide 2.4 mg | 99 | -9.5% | 6.2 |
| Cagrilintide 4.5 mg | 97 | -10.8% | 5.5 |
| Liraglutide 3.0 mg | 95 | -8.5% | 5.6 |
| Pooled Placebo | 95 | -3.0% | 5.2 |
These are the registry's descriptive means and standard deviations. They are not the paper's modeled trial-product means, a dose-specific nausea table or a recommended amount. The liraglutide comparator was once daily; the cagrilintide groups were once weekly.
The registry reports descriptive weight changes with the number of participants contributing to each group. These are separate from the paper's modeled estimand results. Neither table, by itself, measures receptor occupancy or establishes a clinically optimal dose.
REDEFINE 1 assigned 3,417 participants to four groups: CagriSema, semaglutide alone, cagrilintide alone or placebo. The target was 2.4 mg for each active component; a target dose does not mean every participant remained on that dose at week 68.
Why 2.4 mg became the focus dose
The selected sources document the studied targets and observed outcomes. They do not verify the earlier manufacturing-cost, receptor-saturation or commercial-likelihood explanation for choosing 2.4 mg.
The descriptive registry means are -9.5% at 2.4 mg and -10.8% at 4.5 mg, a 1.3 percentage-point difference. This is not the earlier 0.7-point claim and is not a modeled head-to-head treatment estimate. Calling the curve a plateau requires more than substituting approximate values.
The phase 2 abstract reports gastrointestinal events across cagrilintide groups and similar permanent discontinuation across treatment groups overall. It does not supply the former table's dose-specific labels of low, moderate, manageable or highest nausea.
Both CagriSema target amounts are 2.4 mg in REDEFINE 1. Equal numerical targets do not mean equal potency, identical escalation or proof that the pairing was selected to simplify manufacturing.
The selected trial publications do not provide a manufacturing-cost comparison or establish why a commercial dose would be chosen.
REDEFINE 1 includes separate combination, semaglutide, cagrilintide and placebo groups. Its design should be described directly rather than characterized as a single-dose trial for presumed statistical efficiency.
2.4 mg is a documented target in the later studies. That factual statement does not require a prediction about commercial labeling or a claim that it is the most studied dose across all research.
The titration schedule used in trials
The escalation sequence depends on the named study and assigned target. The table below transcribes the cagrilintide groups in NCT03856047. The trial used a 26-week treatment period with escalation of up to six weeks.
| Target group | Week 0 | Week 2 | Week 4 | Week 6 onward |
|---|---|---|---|---|
| 1.2 mg | 0.6 mg | 1.2 mg | 1.2 mg | 1.2 mg |
| 2.4 mg | 0.6 mg | 1.2 mg | 2.4 mg | 2.4 mg |
| 4.5 mg | 0.6 mg | 1.2 mg | 2.4 mg | 4.5 mg |
The phase 1b combination study instead co-escalated cagrilintide and semaglutide in four-week intervals over 16 weeks, followed by four weeks at target. A four-week monotherapy target step, a six-week maximum escalation and a 16-week combination escalation are different protocol details.
The prior generalized nine-week schedule and clinical-experience assertion were not supported by the selected protocols. The studies do not establish a rule for faster escalation in people previously using another GLP-1 treatment.
Injection technique and frequency
Cagrilintide is administered by subcutaneous injection once weekly. Subcutaneous means in the fatty layer beneath the skin, not into a muscle or vein. Common injection sites:
- Abdomen (avoiding the area immediately around the navel)
- Front of thigh
- Back of upper arm
Patients in trials rotate sites to avoid lipohypertrophy (fatty tissue buildup at repeated injection sites). The needle is typically a short, fine gauge (similar to GLP-1 medication needles), and the injection itself is brief.
Pre-filled pens are the standard delivery format in development. In trials, patients learn injection technique from study staff and practice under supervision before self-administering at home. The technique is comparable to semaglutide or tirzepatide self-injection.
The phase 1b study measured a cagrilintide half-life of 159-195 hours, approximately 6.6-8.1 days, across studied combination cohorts. A measured half-life is not a clinical result for a missed dose, though missed doses should be reported to the study team.
Why dose-response flattens at higher doses
The phase 2 study compared several assigned doses. Its descriptive outcome means and modeled analyses should stay labeled separately. A weight-change curve does not directly measure human receptor occupancy.
The selected weight trials do not measure receptor saturation at the 2.4 mg target.
The former near-maximal receptor-occupancy claim cannot be derived from the selected weight outcomes. A mechanistic binding study and a clinical dose-finding study answer different questions.
The publications document the selected study targets without establishing the prior mechanistic-ceiling explanation. Trial interpretation does not require assigning an undocumented motive to the development team.
How CagriSema combines cagrilintide and semaglutide dosing
REDEFINE 1 studied a CagriSema target of 2.4 mg cagrilintide plus 2.4 mg semaglutide weekly. The trial allowed dose flexibility; assigned target and dose actually received at a time point are separate variables.
The investigator's REDEFINE 1 presentation, slide 20, distinguishes the highest dose reached at any point from the dose at week 68.
| Group | Randomized group size | Top dose at week 68 | Highest target dose at any point |
|---|---|---|---|
| Cagrilintide alone | 302 | 249 (82.5%) | 288 (95.4%) |
| CagriSema | 2108 | 1208 (57.4%) | 1575 (74.7%) |
The presentation reports 1,208 people (57.4%) on the CagriSema target dose at week 68 and a randomized group size of 2,108. Dividing those displayed counts gives 57.31%, or 57.3% to one decimal, so the published percentage does not exactly reproduce from the headline randomized count. The analysis denominator matters. This is a time-point dose count, not a claim that everyone outside that group discontinued. These observed dose groups do not establish the causal benefit of choosing a lower dose.
The mechanism rationale: cagrilintide and semaglutide act through different receptors (amylin and GLP-1, respectively). Combining them activates complementary pathways, potentially producing greater appetite suppression and weight loss than either alone.
The REDEFINE 1 paper reports -20.4% mean weight change with CagriSema versus -3.0% with placebo under its treatment-policy estimand. The presentation also reports -22.7% under the trial-product estimand. These are different statistical questions within the same trial, not interchangeable headline numbers or a direct comparison with tirzepatide from another trial.
Whether the incremental benefit of cagrilintide on top of semaglutide justifies the additional cost, complexity, and side-effect burden is a question commercial and regulatory analysis will address.
The gray-market dosing problem
Some online sellers offer products labeled as cagrilintide with dosing instructions written by unofficial sources. These instructions are unreliable for several reasons.
Identity verification. Gray-market sellers do not have to prove that what is in the vial matches the label. Independent testing of products labeled as semaglutide or tirzepatide from unauthorized suppliers has found substantial variation, including products containing no active ingredient or different drugs entirely. The same risk applies to products labeled as cagrilintide.
Concentration variability. Even if the product contains cagrilintide, the labeled concentration may not match actual concentration. A patient who carefully calculates a "2.4 mg" dose based on a labeled concentration may receive a substantially different actual dose.
Sterility. Injectable products require sterile manufacturing. Gray-market suppliers operate outside FDA quality oversight. Contamination with bacteria, endotoxins, or particulates is a real risk.
No medical supervision. Trial patients have access to study teams for managing side effects, lab monitoring, and dose adjustment. Self-injecting from a gray-market vial without supervision means GI side effects, blood pressure changes, or rare adverse events have no clinical safety net.
The contrary view: dose may differ in commercial labeling
The 2.4 mg dose used in trials is the development priority, but commercial labeling could differ. Several scenarios:
FDA labeling might recommend a different dose range based on full phase 3 data. If a lower dose produces acceptable efficacy with better tolerability in a subgroup analysis, labeling might recommend 1.7 mg or 2.0 mg as the standard target with optional escalation to 2.4 mg.
Labeling might recommend slower titration than trials used. If real-world tolerability in less-supervised settings is worse than in trials, the FDA may require a more conservative titration schedule.
Labeling might recommend cap doses for specific patient populations. Patients with hepatic impairment, renal impairment, or specific drug interactions might be limited to lower doses.
CagriSema labeling (if approved) might differ from monotherapy cagrilintide labeling. The combination's dosing may be locked at 2.4 mg + 2.4 mg or might offer alternative ratios.
Patients should rely on FDA-approved labeling once available, not on trial-era dosing assumptions.
Decision framework for patients considering trials
If you are interested in accessing cagrilintide today, clinical trial participation is the only legitimate path.
To explore trial participation:
- Search clinicaltrials.gov for "cagrilintide" or "CagriSema" to find currently enrolling trials
- Verify enrollment criteria (BMI, comorbidities, prior weight loss attempts, contraindications)
- Contact the trial site listed in the registry
- Discuss with your current clinician whether trial participation makes sense given your health profile
If trial participation is not feasible or you do not match enrollment criteria, currently available alternatives include:
- FDA-approved semaglutide (Wegovy) for similar mechanism without the amylin component
- FDA-approved tirzepatide (Zepbound) for greater mean weight loss
- Older amylin pathway option: pramlintide (Symlin), FDA-approved for diabetes, used off-label rarely for weight loss
Do not source cagrilintide from unauthorized suppliers. The risk profile is not acceptable for the clinical benefit, especially when alternative approved therapies exist.
FAQ
How much cagrilintide can I take weekly?
Cagrilintide is investigational and not FDA-approved, so there is no approved patient dose. The phase 2 trial assigned weekly targets of 0.3, 0.6, 1.2, 2.4 and 4.5 mg. The later REDEFINE 1 target was 2.4 mg, with dose flexibility. The selected evidence does not establish the earlier optimal-dose or mechanistic-ceiling claims. FormBlends does not prescribe or supply cagrilintide.
What is the starting dose of cagrilintide?
The registered phase 2 groups targeting 1.2, 2.4 or 4.5 mg started at 0.6 mg; the 0.3 and 0.6 mg groups were separate assigned targets. The phase 1b combination study used its own co-escalation schedule. Patients should not interpret trial dosing as a self-administration protocol; cagrilintide is investigational and any access outside a trial is unauthorized.
How much cagrilintide should I take?
There is no FDA-approved dose for cagrilintide because the drug is not approved. Patients should not be taking cagrilintide outside of an authorized clinical trial. Online dose recommendations from unofficial sources do not reflect medical guidance. The trials have used 2.4 mg weekly as the primary dose, but this is research dosing, not patient dosing.
How often is cagrilintide injected?
The selected trials administered cagrilintide once weekly by subcutaneous injection. The phase 1b study measured a half-life of 159-195 hours across its combination cohorts; this does not supply a missed-dose clinical comparison.
Why is 2.4 mg the most-studied dose?
2.4 mg is the cagrilintide target used in REDEFINE 1, including a monotherapy group. The selected sources do not establish the former all-research most-studied ranking, preferred tradeoff or manufacturing rationale.
Can cagrilintide be combined with other GLP-1 drugs?
How is cagrilintide injected?
In clinical trials, cagrilintide is administered as a subcutaneous injection in the abdomen, thigh, or upper arm. The technique is similar to other GLP-1 injectables. Injection site rotation is standard practice to prevent lipohypertrophy. Patients in trials receive specific instructions from study staff; outside of trials, cagrilintide is not legally available.
Related guides
- How to Reconstitute Cagrilintide: An Educational Overview
- Tool: dosage calculator
Sources
- Registered phase 2 groups and results, NCT03856047.
- Phase 2 monotherapy paper, PMID 34798060.
- Phase 1b combination paper, PMID 33894838.
- REDEFINE 1 paper, PMID 40544433.
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. The Lancet. 2021;398:2160-2172.
- Enebo LB, Berthelsen KK, Kankam M, et al. Concomitant administration of cagrilintide with semaglutide 2.4 mg. The Lancet. 2021;397:1736-1748.
- Novo Nordisk. REDEFINE-1 Phase 3 results, press release. December 2024.
- Hay DL, Chen S, Lutz TA, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews. 2015;67(3):564-600.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384:989-1002. (STEP 1)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387:205-216. (SURMOUNT-1)
- ClinicalTrials.gov. Registry of active cagrilintide and CagriSema trials. Accessed May 2026.
- U.S. Food and Drug Administration. Symlin (pramlintide acetate) Prescribing Information. 2005, revised.
- Novo Nordisk. Pipeline development updates for cagrilintide and CagriSema. novonordisk.com.
Footer disclaimers
Compounded Medication Notice. 503A compounding of cagrilintide is not authorized through standard FDA shortage pathways. Some compounding pharmacies have offered "research peptides" labeled as cagrilintide; these are not equivalent to FDA-recognized clinical trial materials and are not FDA-approved. Patients should not pursue access through these channels.
Results Disclaimer. Trial dose-response data cited in this article reflect averages from published clinical studies. Individual response varies. Trial protocols include monitoring and safety nets that self-administration outside of trials lacks.